Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Oligodendroglioma/Oligodendroglial tumors
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 51 for your search:
Start Over
Radiation Therapy with or without Temozolomide in Treating Patients with Anaplastic Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0834, NCI-2011-02070, CAN-NCIC-CEC1, CDR0000582632, COGNO-EORTC-26053, EORTC-22054, EORTC-26053, EUDRACT-2006-001533-17, MERCK-EORTC-26053, MRC-BR14, SPRI-EORTC-26053, CEC1, NCT00626990
Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients with Newly Diagnosed Anaplastic Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Radiation Therapy with or without Temozolomide in Treating Patients with Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E3F05, NCI-2011-01971, CDR0000654697, ECOG-E3F05, NCT00978458
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: SOL-04058-L, NCI-2013-00786, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, NCT01325207
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BTTC09-01, NCI-2011-03056, NCT01434602
Bevacizumab with or without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients with Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1174, NCI-2012-01989, CDR0000737109, NCCTG-N1174, NCT01648348
Carboxyamidotriazole Orotate with or without Bevacizumab in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00044274, NCI-2014-00031, NCT01954030
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, NCT01977677
Carboxyamidotriazole Orotate with or without Lomustine in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00047969, NCI-2014-00304, NCT01989052
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, eIRB #922, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Bendamustine Hydrochloride in Treating Patients with Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 6803, NCI-2010-00714, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
Aminolevulinic Acid in Measuring Brain Tumors in Patients With High Grade Glioma Undergoing Surgery
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 to 72
Trial IDs: 10101, NCI-2011-01264, NCT01116661
Nilotinib in Treating Patients with Recurrent Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 091728, NCI-2010-01839, NCT01140568
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas and Favorable Grade 3 Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-439, NCI-2011-00915, NCT01358058
Aminolevulinic Acid Hydrochloride in Visualizing Tumors in Patients with Newly Diagnosed or Recurrent Malignant Gliomas Undergoing Surgery
Phase: Phase II
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: WCI1999-11, NCI-2011-03426, IRB00051663, NCT01445691
Ondansetron with or without Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Gliomas
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: Pro00031206, NCI-2013-00520, NCT01450826
Hypofractionated Radiation Therapy in Combination with Temozolomide and Bevacizumab in Treating Patients with Recurrent High-Grade Glioblastoma Multiforme or Anaplastic Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 11C02, NCI-2011-02904, NCI CTRP#, STU00053636, NCT01478321
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Everolimus With or Without Temozolomide in Treating Patients With Newly-Diagnosed Low-Grade Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 131012, NCI-2014-00749, 081184, CRAD001CUS225T, NCT02023905
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 08109, NCI-2011-01701, NCT00823459
Start Over